4 - PALISADE BIO, INC. (0001357459) (Issuer)

4 - PALISADE BIO, INC. (0001357459) (Issuer)

4 - PALISADE BIO, INC. (0001357459) (Issuer)

4 - PALISADE BIO, INC. (0001357459) (Issuer)

4 - PALISADE BIO, INC. (0001357459) (Issuer)

4 - PALISADE BIO, INC. (0001357459) (Issuer)

4 - PALISADE BIO, INC. (0001357459) (Issuer)

4 - PALISADE BIO, INC. (0001357459) (Issuer)

4 - PALISADE BIO, INC. (0001357459) (Issuer)

4 - PALISADE BIO, INC. (0001357459) (Issuer)

4 - PALISADE BIO, INC. (0001357459) (Issuer)

4 - PALISADE BIO, INC. (0001357459) (Issuer)

4 - PALISADE BIO, INC. (0001357459) (Issuer)

4 - PALISADE BIO, INC. (0001357459) (Issuer)

4 - PALISADE BIO, INC. (0001357459) (Issuer)

4 - PALISADE BIO, INC. (0001357459) (Issuer)

4 - PALISADE BIO, INC. (0001357459) (Issuer)

Data from Pooled-Analysis of Enteral Protease Inhibitor LB1148 Demonstrated 72% Reduction in the Risk of Adhesion Formation in Patients Undergoing Bowel Resection Surgery Company to Host Conference Call on Wednesday, March 16, 2022, at 8:30 a.m. EDT CARLSBAD, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN.) These data are featured today at the Next Big Thing session of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 202

Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects, potentially enhancing patient compliance compared to existing PDE4 inhibitors Data presented at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting Carlsbad, CA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a biopharmaceutical company dedicated to developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases has announced the presentation of data from two translational s

Carlsbad, CA, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepted for poster presentation at ACG's 2024 Annual Scientific Meeting being held October 25-30, 2024 in Philadelphia, PA. The American College of Gastroenterology (ACG) is a recognized leader in educating GI professionals and the general public about digestive disorders. For more information about the ACG Annual Meeting, please visit the conference website. A

– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA) – The study is a Phase 1 Single Ascending Dose (SAD) /Multiple Ascending Dose (MAD) and food effects (FE) and includes multiple dose treatment of UC patients; Global UC market is expected to grow to nearly $10 Billion by 2028 Carlsbad, CA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has received a No Objec

– Live webcast fireside chat on Tuesday, October 15th at 4:30 PM ET Carlsbad, CA, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that J.D. Finley, Chief Executive Officer and Dr. Mitch Jones, CMO of Palisade Bio will participate in a fireside chat at the 2024 Healthcare Virtual Summit, presented by Maxim Group LLC on Tuesday, October 15, 2024 at 4:30 PM ET. Maxim Senior Analysts will host a wide range of biotechnology, diagnostic, medical device, and h

– Completion of nonclinical safety and toxicity studies, Phase 1 clinical trial design and established Maximum Recommended Starting Dose – Completion of pre- Clinical Trial Application (CTA) meeting with Health Canada – Submission of the CTA for the Phase 1 clinical study of Normal Healthy Volunteers and ulcerative colitis patients – On track towards clinical site initiation and dosing of first patient in Phase 1 human clinical study before year end Carlsbad, CA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients livin

– Company remains committed to its mission to become a leader in developing differentiated product candidates targeting immune, inflammatory and fibrotic diseases – Successful completion of nonclinical safety and toxicity studies and continued execution of regulatory requirements towards launch of Phase 1 human clinical study for lead program, PALI-2108 for the treatment of UC before year end Carlsbad, CA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today anno

Curated data show expression of PDE4B above a specific measurable threshold observed in 70% of adult colitis patients and 90% of pediatric colitis patients Company is advancing lead program PALI-2108, an orally administered, locally acting colon-specific PDE4 inhibitor prodrug in development for patients affected by Ulcerative Colitis (UC) Phase 1 human clinical study of PALI-2108 for the treatment of UC on track to commence before year end Carlsbad, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio," or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with

Carlsbad, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it had made an equity grant to a new employee under its 2021 Inducement Plan, as amended. The Company's Compensation Committee approved the issuance of an option to purchase 5,000 shares of the Company's common stock to Joerg Heyer, the new Head of Translational Science and Medicine, as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The op

– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Company continues to establish growing body of preclinical data for PALI-2108 and global patent estate – Sufficient cash on hand to execute on current business plan and reach clinical and regulatory milestones through first quarter of 2025 Carlsbad, CA, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic d

– Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before year end – Based on the modeling and simulations, Palisade has established dose levels and trial design for PALI-2108 Carlsbad, CA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today provided a progress update on the advancement of development for its lead drug candidate, PALI-2108 towards initiation of Phase 1 clinical trials in healthy volunteer

Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programsPatent includes broad claims for "Gut Microbiota Bioactivated PDE4 Inhibitor Precursors" with similar structure to PALI-2108 and PALI-1908This patent family provides Composition of Matter coverage beyond 2042PALI-2108 is in development to treat patients with active moderate-to-severely active Ulcerative Colitis (UC)PALI-1908 is in development to treat patients with active fibro stenotic Crohn's Disease (CD)

– Collaboration advancing Palisade Bio's precision medicine approach through access to cutting-edge expertise and tools in bioinformatics– Candidate PDE4-related biomarkers overlapping with UC pathophysiology have been identified and innovative selection strategy development is underway

PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposureCompany on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of UC before year end

Data presented at Digestive Disease Week (DDW) 2024Preclinical data demonstrate PALI-2108 to be safe, effective, and well toleratedPALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposurePALI-2108 exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human use in Ulcerative Colitis (UC) patientsCompany on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of UC before year end

Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(4.59) per share which missed the analyst consensus estimate of $(4.28) by 7.24 percent. This is a 43.54 percent increase over losses of $(8.13) per share from the same period last year.

Gainers NeuBase Therapeutics (NASDAQ:NBSE) stock increased by 11.1% to $0.45 during Friday's after-market session. The market value of their outstanding shares is at $1.6 million. Aptevo Therapeutics (NASDAQ:APVO) shares moved upwards by 7.17% to $1.06. The company's market cap stands at $3.8 million. Galera Therapeutics (NASDAQ:GRTX) shares moved upwards by 6.72% to $0.2. The market value of their outstanding shares is at $10.7 million. Alzamend Neuro (NASDAQ:ALZN) shares rose 5.85% to $0.77. The company's market cap stands at $5.2 million. Asensus Surgical (AMEX:ASXC) shares increased by 5.43% to $0.25. The company's market cap stands at $69.1 million. cbdMD (AMEX:YCBD) stock rose 5.

Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Margery Fischbein to its Board of Directors. Ms. Fischbein is a highly experienced healthcare investment banker and accomplished biotechnology industry executive. "We are excited to welcome Ma

Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (NASDAQ:PALI) ("Palisade" or the "Company"), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced a correction to its press release originally issued on February 8, 2024, announcing the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinical Advisory Board (CAB). In the original press release, it was incorrectly stated that the PALI-2108 development program was on track to commence a Phase 1 clinical study next year. The Company reiterates its guidance that the PALI-2108 Phase 1 clinical study is on track to launch in 20

Bruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenterology, Mount Sinai Health SystemFlorian Rieder, MD, Associate Staff in the Department of Gastroenterology, Hepatology, and Nutrition, as well as an Investigator in the Department of Pathobiology at the Cleveland Clinic Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinic

Announces Awarding of Inducement Grant to New Chief Medical Officer Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the appointment of Mitchell Jones, M.D., Ph.D., as Chief Medical Officer. Dr. Jones has a proven track record of successfully developing oral biotherapeutics and locally acting immunomodulating therapeutics designed to act locally within the gastrointestinal tract, including for inflammatory bowel disease. Throughout his career, Dr. Jones has established a reputation for not on

SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the appointment of Richard John Daly ("Mr. Daly") as the President of CARsgen Therapeutics Corporation, a subsidiary of the Company in the United States. Mr. Daly will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Mr. Daly will lead the CARsgen U.S. team for the international business activities of CARsgen outside of China, including clinical development, CMC operation, busin